Functional and Reconstructive Urology (FRU) is a rapidly expanding subspecialty in Urology. Some may call it rebranding, others call it a blending of existing subspecialties including Female Urology, Neuro-urology, Urodynamics, BPH, Prosthetic Urology, Men’s Health and Reconstructive Urology. Regardless of the name, the vision of the subspecialty is to improve the management of patients with urinary...

This Men's Health NGLC covers topics in Andrology, AUA Guidelines, Sexual Health, Incontinence, BPH, and other topics in Men's Health.

As a result of an increasing amount of clinical data, interest in focal ablation for the treatment of localized prostate cancer has grown immensely over the last fifteen years. We are Drs. Arvin George, Abhinav Sidana, and Jonathan S. Fainberg, internationally-recognized experts in focal therapy. As editors of the Grand Rounds in Urology Next Generation Focal...

There is an abundance of evidence that the human microbiome plays an important and nuanced role in controlling human health, including metabolism, immunity, pain, psychological state, and cancer.

The role of genetic testing for prostate cancer risk is a rapidly changing area. Experts debate the indications of sending a patient on to genetic counseling for further potential screening for inherited prostate cancer risk. One major issue that needs to be addressed in the urology community today is recognizing the frequency of inherited mutations that...

Latest prostate cancer research is turning its focus on the M0 space. Many therapeutic options for castration-resistant prostate cancer are approved and used for metastatic castration-resistant prostate cancer (mCRPC), but fewer options exist for those with non-metastatic (NM) CRPC.

The role of imaging is paramount in this evolution by providing physicians with accurate information on both the presence and extent of prostate cancers. Developments in molecular imaging are paving the way for more physicians to diagnose cancer and apply relevant therapy.

One of the major treatments for prostate cancer is androgen-deprivation therapy (ADT), and about 50% of prostate cancer patients are treated with ADT at some point in their disease. ADT is used most frequently for patients with local but advanced prostate cancer or metastatic prostate cancer.

Upper tract urothelial carcinoma (UTUC) is cancer of the transitional urothelial cells that line the upper urothelial tract of the renal pelvis and ureter. This type of cancer accounts for between 5% and 10% of urothelial cancer cases.

These lectures were presented during the Presentations from 1st International Functional and Reconstructive Urology Update in August 2024, in Denver, Colorado.

These lectures were presented during the 24th Annual Future Directions in Urology Symposium in August 2024, in Colorado Springs, Colorado.

These lectures were presented during the 33rd Annual International Prostate Cancer Update in January 2023, in Vail, Colorado.

These lectures were presented during the 33rd Annual International Prostate Cancer Update in January 2023, in Vail, Colorado.

These lectures were presented during the 6th Annual International Bladder Cancer Update on November 18, 2022, in Scottsdale, Arizona.

These lectures were presented during the 2nd Annual Advances in Men's Health in August 2022, in Big Sky, Montana.

These lectures were presented during the 32nd Annual International Prostate Cancer Update in March 2022, in Snowbird, Utah.

In a program supported by Verity Pharmaceuticals, E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology and Professor of Urology at the University of California, San Diego; Neal D. Shore, MD, FACS, Medical Director for the Carolina Urologic Research Center; and Benjamin H. Lowentritt, MD, FACS, Director of Prostate Cancer Services for United Urology Group...

These lectures were presented during the 1st Annual Advances in Men's Health conference in August 22-25, in Whitefish, Montana.

These lectures were presented during the 31st Annual International Prostate Cancer Update in July 2021, in Snowbird, Utah.

In a GRU exclusive series, Franklin Gaylis, MD, FACS, discusses how the urology field can use the electronic medical record, or EMR, to improve adherence to best medical practices in prostate cancer care.

In a GRU exclusive series, Sigrid V. Carlsson, MD, PhD, MPH, discusses PSA screens, biopsy, and MRI for early detection.

In a GRU exclusive, Abraham Morgentaler, MD, FACS, Associate Clinical Professor of Urologic Surgery at Harvard University, reviews lectures from all three days of the 3rd Annual Androgen Society meeting.

These lectures were presented during the 4th Annual International Bladder Cancer Update on April 28.

In a GRU exclusive, Laurence Klotz, MD, FRCSC, Professor of Surgery and holder of the Sunnybrook Chair of Prostate Cancer Research at the University of Toronto, gives three Platinum Lectures on the current state of active surveillance for prostate cancer.

These lectures were presented during the 5th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer, presented over four successive weeks throughout October, 2020.

These lectures were presented during the Perspectives in Urology Point • Counterpoint Virtual Conference on November 11, 2020.

These lectures were presented during the 5th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer, presented over four successive weeks throughout October, 2020.

The 2020 Virtual Southwest Prostate Cancer Symposium (SPCS 2020) is intended for urologists, radiation oncologists, medical oncologists, and other healthcare professionals involved in the treatment of prostate cancer. It will educate the attendees about advances in the management of localized and advanced prostate cancer, with a focus on imaging, technology, and training in the related devices.

These lectures were presented during the 2020 Virtual Future Directions in Urology Symposium on August 10, 2020.